|
|
 |
|
Viewing report
|
|
|
|
Advances in Peptide Therapeutics - Technical Insights
Frost & Sullivan, Sep 2010, Pages: 61
This Frost & Sullivan research service titled Advances in Peptide Therapeutics provides an overview of the peptide therapeutics industry, the major stakeholders, the market drivers, industry challenges, and a prioritized recommendation for R&D portfolio design. The study distinguishes basic peptides, target discovery platforms, and applied options such as software or delivery technologies, as options for designing an R&D portfolio.
This analysis is available through our Technical Insights program. With this program, clients receive industry-leading market research along with comprehensive, objective information that allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Technology Overview
Streamlined Manufacturing Processes Ensure Strong Traction for Peptide Therapeutics
Therapeutic peptides are one of the most attractive options in recombinant medicine. This is due to their low toxicity, high specificity, and much lower molecular weight that makes it easier to set up dosage plans for patients. Although therapeutic peptides were introduced into the market twenty years ago, they witnessed greater uptake only during the past five or six years. Improvements in the manufacturing process and delivery systems have triggered a revival of interest among consumers. ”Several large pharmaceutical companies are avidly funding detailed research in this field,” notes the analyst of this research service. “Emerging therapeutic areas for peptides such as anti-infectives, vaccines, and central nervous system (CNS)-targeting peptides can well set the stage for a new class of drugs in these areas.” Peptide therapeutics is a topic of high interest for both research and manufacture. An already established market for these entities makes it easier to introduce peptides in previously unexplored areas such as anti-microbials and vaccines. This sector is poised for a boost with high funding inflows and collaboration between big pharmaceuticals, small biotechs, academia, and contract manufacturing organizations.
A major point-of-concern is effective portfolio design to take advantage of the therapeutic areas that have the highest market potential. This information is important to three categories of participants in peptide therapeutics, namely big pharmaceutical companies, small biotech companies, and contract manufacturing organizations. The recent economic crisis had caused significant shifts in the funding scenario for the growing therapeutic peptides market. This was clearly reflected in the investment prioritization for big pharmaceutical companies. They are more willing to invest in early stage development in the presence of a promising candidate (revenue-wise) and technology platform with strong backing. Portfolio management approaches differ among stakeholders. Small biotech companies focus on a single product or technology, while big pharmaceutical companies maintain a diverse portfolio by therapeutic area and focus on collaborations, mergers and acquisitions (M&A), and licensing. This creates a gap in stakeholder interconnections in this industry. Cost-intensive manufacturing processes present barriers for small biotech companies that can synthesize peptides but cannot get to the stage of market entry. Lastly, alternative de-risking approaches such as small molecules can be better for some diseases, therefore, restricting the entry of therapeutic peptides in that area.
In the future, peptide therapeutics holds huge promise from a medical point of view for both patients and drug companies. Cost optimization in manufacturing and the development of non-invasive delivery technologies will go a long way in generating robust revenue growth for this sector and lead to better treatment outcomes for the patient. “Efficient target discovery platforms and further research on peptide stability will greatly assist the manufacturing process,” concludes the analyst. “The advent of new manufacturing methods in solid-phase production will help scale down the production cost for peptides.”
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
